
CLAIMS

1. Use of a compound of the following structural formula:



,

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Gaucher disease in a subject who has been assessed as being a poor, intermediate or extensive P450 metabolizer,

wherein the administration pattern of the medicament comprises administering an effective amount of the compound if the subject is assessed as a poor metabolizer; and administering the compound in an adjusted effective amount if the subject is assessed as an intermediate or extensive P450 metabolizer, wherein said adjusted effective amount is greater than said effective amount.

2. Use according to claim 1, wherein said P450 is CYP2D6 or CYP3A4.

3. Use according to claim 1 or 2, wherein said subject has been assessed as being a poor, intermediate or extensive metabolizer through genotyping.

4. Use according to claim 3, wherein said subject has been assessed as being a poor metabolizer as a result of carrying two mutant alleles of the CYP2D6 gene which result in complete loss of enzyme activity.

5. Use according to claim 1 or 2, wherein said subject has been assessed as being a poor metabolizer as a result of low expression of said P450.

6. Use according to claim 1 or 2, wherein said subject has been assessed as being a poor metabolizer as a result of being treated with a drug that is an inhibitor of said P450.

7. Use according to claim 6, wherein said subject possesses one reduced activity allele and one null allele of CYP2D6, or wherein said subject possesses at least one and no more than two normal functional alleles of CYP2D6.

8. Use according to claim 6 or 7, wherein said drug is paroxetine, fluoxetine or quinidine.

9. Use according to any one of claims 4 to 8, wherein the administration pattern of the medicament comprises administering the compound in a daily dose of from 25 milligrams to 150 milligrams.

10. Use according to any one of claims 4 to 8, wherein the administration pattern of the medicament comprises administering the compound in a daily dose of from 50 milligrams to 100 milligrams.

11. Use according to claim 3, wherein said subject has been assessed as being an intermediate metabolizer as a result of possessing one reduced activity allele and one null allele of the CYP2D6 gene.

12. Use according to claim 3, wherein said subject has been assessed as being an extensive metabolizer as a result of possessing at least one and no more than two normal functional alleles of the CYP2D6 gene.

13. Use according to any one of claims 1 to 3, wherein the administration pattern of the medicament comprises administering the compound at said adjusted effective amount, this being a dose of greater than 100 milligrams per day.

14. Use according to any one of claims 11 to 13, wherein the administration pattern of the medicament comprises administering the compound in a daily dose of from 100 milligrams to 300 milligrams.

15. Use according to any one of claims 11 to 14, wherein the administration pattern of the medicament comprises administering the compound in a dose of greater than 150 milligrams per day.

16. Use according to any one of claims 1 to 15, wherein said subject is a human patient.

17. Use according to any one of claims 1 to 16, wherein said Gaucher disease is type 1 Gaucher disease.

18. Use according to any one of claims 1 to 17, wherein the compound is represented by the hemitartrate salt of said structural formula.